The GLP-1 receptor agonists segment dominated the market with a share of 86% in 2025, as GLP-1 receptor agonists are driving historic market expansion by transforming obesity and diabetes management into a billion-dollar global industry
FDA prescribing information for these medications includes warnings about the risk of acute kidney injury in patients who experience severe adverse gastrointestinal reactions
[DOI] [PMC free article] [PubMed] [Google Scholar] 90.Bukowska-Strakova K., Wodek J., Pitera E., Kozakowska M., Konturek-Ciela A., Ciela M., Goka M., Nowak W., Wieczorek A., Pawiska-Wsikowska K., et al
Why This Formula Exists NMN21000 combines an NMN-led NAD+ precursor direction with supporting nutrients selected for methylation, antioxidant, cellular-energy, and bone-health routines
The underlying processes are complex and only partly understood